Alan Gottlieb

Pramlintide: A Human Amylin Analogue Reduced Postprandial Plasma Glucose, Insulin, and C‐peptide Concentrations in Patients with Type 2 Diabetes

O. Kolterman, A. Gottlieb, R. G. Thompson, 1997, Diabetic medicine : a journal of the British Diabetic Association.

Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM

S. Schwartz, O. Kolterman, B. Levy, 1996, Diabetologia.

Reduction of Postprandial Hyperglycemia in Subjects With IDDM by Intravenous Infusion of AC137, a Human Amylin Analogue

W. Colburn, O. Kolterman, A. Gottlieb, 1995, Diabetes Care.

Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

Dennis D. Kim, C. Weyer, S. Schwartz, 2003, Diabetes care.

Pharmacokinetics and Pharmacodynamics of AC137 (25,28,29 Tripro‐Amylin, Human) After Intravenous Bolus and Infusion Doses in Patients with Insulin‐Dependent Diabetes

W. Colburn, O. Kolterman, A. Gottlieb, 1996, Journal of clinical pharmacology.

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.

L. Want, C. Weyer, M. Fineman, 2002, Diabetes technology & therapeutics.